Follow us on:

N4 Pharma CEO Nigel Theobald excited with siRNA programme (VIDEO)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss results for the year ended 31 December 2022.

Nigel explains how the market for N4 Pharma has changed in recent times, the findings from a strategic review of Nuvec as a delivery system, why the siRNA programme has taken greater prominence, the potential market for this programme and what investors can expect from N4 Pharma in 2023.

N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

More News

N4 Pharma successfully completes in vivo confirmatory oncology study reinforcing the results from earlier pilot study December 13, 2021
N4 Pharma EPO has now formally granted European Patent October 1, 2021
N4 Pharma acceleration in understanding of the capabilities of Nuvec September 20, 2021
N4 Pharma pleased with initial in vitro results from new SARS-COV-2 plasmid September 14, 2021
N4 Pharma enters into two MTAs and good progress with in vivo work programme May 20, 2021
N4 Pharma in a stronger position for collaborations February 24, 2021
N4 Pharma raises £2 million through placing December 9, 2020
N4 Pharma update on Nanomerics research collaboration December 3, 2020
N4 Pharma appoints Nanomerics to investigate potential utility of Nuvec in cancer therapy November 9, 2020
N4 Pharma make significant strides with optimisation work November 5, 2020

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.